DNA damage repair in breast cancer and its therapeutic implications.

[1]  A. Cox,et al.  Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy , 2016, Oncotarget.

[2]  Trey Ideker,et al.  A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. , 2016, Molecular cell.

[3]  D. Ogilvie,et al.  A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase. , 2016, Analytical biochemistry.

[4]  Ian O. Ellis,et al.  Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer , 2016, Oncotarget.

[5]  E. Friedman,et al.  The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. , 2016, Cancer genetics.

[6]  G. Ball,et al.  Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. , 2016, Carcinogenesis.

[7]  B. Waszkowycz,et al.  Abstract C39: First-in-class inhibitors of the putatively undruggable DNA repair target Poly(ADP-ribose) glycohydrolase (PARG) , 2015 .

[8]  Kenric Leung,et al.  The Life History of 21 Breast Cancers , 2015, Cell.

[9]  I. Ellis,et al.  DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers , 2015, Oncotarget.

[10]  A. Chen,et al.  A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). , 2015 .

[11]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[12]  I. Ellis,et al.  DNA damage response markers are differentially expressed in BRCA-mutated breast cancers , 2015, Breast Cancer Research and Treatment.

[13]  G. Ball,et al.  Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer , 2015, Molecular Cancer Therapeutics.

[14]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Ball,et al.  Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy , 2015, Molecular oncology.

[16]  A. Psyrri,et al.  Beyond BRCA: new hereditary breast cancer susceptibility genes. , 2015, Cancer treatment reviews.

[17]  Wei-jia Gao,et al.  The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case–control studies , 2015, Molecular Genetics and Genomics.

[18]  I. Ellis,et al.  Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers? , 2014, Antioxidants & redox signaling.

[19]  Bo Gao,et al.  Association between RECQL5 genetic polymorphisms and susceptibility to breast cancer , 2014, Tumor Biology.

[20]  B. Waszkowycz,et al.  Abstract 2745: Pharmacological characterisation of cell active inhibitors of Poly(ADP-ribose) glycohydrolase (PARG) , 2014 .

[21]  G. Ball,et al.  Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer , 2014, Molecular oncology.

[22]  Zihui Xu,et al.  Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  Weiying Zhou,et al.  TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes , 2014, Molecular Cancer Research.

[24]  E. Winer,et al.  Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Jenny C. Chang,et al.  Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells , 2014, Oncotarget.

[26]  J. Hoeijmakers,et al.  Understanding nucleotide excision repair and its roles in cancer and ageing , 2014, Nature Reviews Molecular Cell Biology.

[27]  James H. Doroshow,et al.  Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[28]  D. Cortez,et al.  ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. , 2014, Cancer research.

[29]  C. Caldon,et al.  Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers , 2014, Front. Oncol..

[30]  T. Dörk,et al.  Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations , 2014, Breast Cancer Research and Treatment.

[31]  Jian-Min Yuan,et al.  Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women. , 2014, Endocrine-related cancer.

[32]  B. Leyland-Jones,et al.  Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. , 2014, Neoplasia.

[33]  P. Jarzemski,et al.  A common nonsense mutation of the BLM gene and prostate cancer risk and survival. , 2013, Gene.

[34]  J. Reis-Filho,et al.  Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[35]  Rodney Rothstein,et al.  Repair of strand breaks by homologous recombination. , 2013, Cold Spring Harbor perspectives in biology.

[36]  A. Paradiso,et al.  BRCAness: a deeper insight into basal-like breast tumors. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[38]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[39]  Xiaojing Guo,et al.  Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer , 2013, Clinical Cancer Research.

[40]  Samuel H. Wilson,et al.  Interaction between DNA Polymerase β and BRCA1 , 2013, PloS one.

[41]  A. Chen,et al.  Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. , 2013 .

[42]  S. Rodenhuis,et al.  Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers , 2013, British Journal of Cancer.

[43]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[44]  Graham Ball,et al.  Targeting XRCC1 deficiency in breast cancer for personalized therapy. , 2013, Cancer research.

[45]  David M. Wilson,et al.  Small Molecule Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1) , 2013 .

[46]  P. Hieter,et al.  An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development , 2013, PLoS genetics.

[47]  R. Brosh,et al.  DNA helicases associated with genetic instability, cancer, and aging. , 2013, Advances in experimental medicine and biology.

[48]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[49]  I. Ellis,et al.  Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer , 2013, Breast Cancer Research and Treatment.

[50]  N. Curtin,et al.  DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin , 2013, Breast Cancer Research and Treatment.

[51]  C. Laughton,et al.  Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors , 2012, International journal of cancer.

[52]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[53]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[54]  G. Tell,et al.  Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers. , 2012, Biochemical and biophysical research communications.

[55]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[56]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[57]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[58]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[59]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[60]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[61]  H. Bryant,et al.  Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells , 2012, Cell cycle.

[62]  C. Eng,et al.  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.

[63]  N. Neamati,et al.  Small-molecule inhibitors of APE1 DNA repair function: an overview. , 2012, Current molecular pharmacology.

[64]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[65]  Y. Pommier,et al.  Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. , 2011, Cancer research.

[66]  E. Cavalieri,et al.  Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  Kwok-Kin Wong,et al.  COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.

[68]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[69]  J. Tainer,et al.  Human Flap Endonuclease Structures, DNA Double-Base Flipping, and a Unified Understanding of the FEN1 Superfamily , 2011, Cell.

[70]  Y. Drew,et al.  Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. , 2011, Journal of the National Cancer Institute.

[71]  Scott H. Kaufmann,et al.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.

[72]  L. Finger,et al.  Functional regulation of FEN1 nuclease and its link to cancer , 2010, Nucleic acids research.

[73]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[74]  John A Tainer,et al.  A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. , 2010, DNA repair.

[75]  S. Elledge,et al.  The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.

[76]  A. Simeonov,et al.  Small molecule inhibitors of DNA repair nuclease activities of APE1 , 2010, Cellular and Molecular Life Sciences.

[77]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[78]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[79]  S. Burma,et al.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. , 2010, Cancer research.

[80]  M. Lieber,et al.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.

[81]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  J. Dahm-Daphi,et al.  The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies , 2010, Nucleic acids research.

[83]  E. Rosen,et al.  Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1* , 2010, The Journal of Biological Chemistry.

[84]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[85]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[86]  P. Ellis,et al.  ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.

[87]  G. Hannon,et al.  The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response , 2009, Proceedings of the National Academy of Sciences.

[88]  T. Helleday,et al.  PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination , 2009, The EMBO journal.

[89]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[90]  J. Parvin,et al.  Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.

[91]  E. Levin,et al.  Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. , 2009, Molecular biology of the cell.

[92]  T. Pandita,et al.  Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair , 2009, Cell cycle.

[93]  E. Alli,et al.  Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. , 2009, Cancer research.

[94]  Hongbing Shen,et al.  A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women , 2009, Breast Cancer Research and Treatment.

[95]  Giu-Cheng Hsu,et al.  Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. , 2009, Carcinogenesis.

[96]  A. Ashworth,et al.  A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.

[97]  I. Ellis,et al.  Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.

[98]  Thomas Helleday,et al.  DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.

[99]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Hiroshi Suzuki,et al.  Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase beta-deficient mice. , 2007, Biochemical and biophysical research communications.

[101]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[102]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[103]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[104]  T. Helleday,et al.  Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair , 2006, Nucleic acids research.

[105]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[106]  Dieter Niederacher,et al.  Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. , 2005, Carcinogenesis.

[107]  M. Sternberg,et al.  Isolation of a small molecule inhibitor of DNA base excision repair , 2005, Nucleic acids research.

[108]  T. Helleday,et al.  Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks , 2005, Molecular and Cellular Biology.

[109]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[110]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[111]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[112]  Zhao-Qi Wang,et al.  Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[114]  A. Ashworth,et al.  DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells , 2004, EMBO reports.

[115]  Huichen Wang,et al.  ATR Affecting Cell Radiosensitivity Is Dependent on Homologous Recombination Repair but Independent of Nonhomologous End Joining , 2004, Cancer Research.

[116]  K. J. Patel,et al.  The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. , 2004, Molecular cell.

[117]  Zhao-Qi Wang,et al.  Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks , 2004, Oncogene.

[118]  Benjamin J. Raphael,et al.  Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability, and cancer in mice , 2004 .

[119]  Zhihui Feng,et al.  Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[120]  Hiroshi Suzuki,et al.  Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice , 1999, Molecular and Cellular Biochemistry.

[121]  T. Helleday,et al.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. , 2003, Nucleic acids research.

[122]  T. Key,et al.  Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.

[123]  S. Powell,et al.  Chk 2 Phosphorylation of BRCA 1 Regulates DNA Double-Strand Break Repair , 2003 .

[124]  Shunichi Takeda,et al.  Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells , 2002, Nature.

[125]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[126]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[127]  M. Kelley,et al.  Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[128]  K. Fidelis,et al.  Functional characterization of Ape1 variants identified in the human population. , 2000, Nucleic acids research.

[129]  M. Kelley,et al.  Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[130]  A. Shinohara,et al.  The controlling role of ATM in homologous recombinational repair of DNA damage , 2000, The EMBO journal.

[131]  C. Anderson,et al.  DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues , 1999, Oncogene.

[132]  P. Chambon,et al.  Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[133]  A. Harris,et al.  Human apurinic endonuclease 1 expression in a colorectal adenoma-carcinoma sequence. , 1997, Cancer research.

[134]  J. Hoeijmakers,et al.  Disruption of Mouse RAD54 Reduces Ionizing Radiation Resistance and Homologous Recombination , 1997, Cell.

[135]  E. Wagner,et al.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. , 1995, Genes & development.

[136]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.